SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Business
Female-Founded and Funded Capsida Taps Swati Tole as Chief Medical Officer
Newly entrenched in a leadership role within one of the most complex therapeutic spaces, Tole discussed the complexities of being both a woman and a woman of color in the biotech industry.
June 1, 2021
 · 
4 min read
 · 
Heather McKenzie
Courtesy of Smith Collection/Gado/Getty Images
Drug Development
AbbVie Hopefuls Skyrizi and Rinvoq Show Promise in Quest to Succeed Humira
AbbVie is aiming Skyrizi and Rinvoq at various indications to augment expected declines in the use of its $20-billion-generating-powerhouse Humira, which will lose patent protection in 2023.
May 25, 2021
 · 
3 min read
 · 
Alex Keown
Win McNamee/Getty Images
Policy
House Oversight Committee Targets AbbVie Over Humira, Imbruvica Price Hikes
House Oversight and Reform Committee slammed AbbVie for price increases on its drugs Humira Imbruvica. It said the company profited from patients and taxpayers.
May 19, 2021
 · 
3 min read
 · 
Alex Keown
Courtesy of Abbvie Inc.
Deals
AbbVie Subsidiary Scoops Up Soliton and Its Cellulite, Tattoo Removal Device
AbbVie’s Allergan Aesthetics’ most well-known brands right now include BOTOX and CoolSculpting, among others. However, with the company’s latest acquisition, another one might slide its way to the top.
May 10, 2021
 · 
2 min read
 · 
Ellen Bombela
A patients story who suffered cystic fibrosis.
Drug Development
Cystic Fibrosis: One Patient’s Story, Current Treatments and Exciting New Therapies on the Horizon
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
May 10, 2021
 · 
13 min read
 · 
Chelsea Weidman Burke, M.S.
Business
Q1 2021: A Look at Top 25 Biopharma Companies by Market Cap
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
May 2, 2021
 · 
14 min read
 · 
Heather McKenzie
Photo courtesy of Capsida Biotherapeutics Inc.
Business
Seeking Safety and Specificity in Gene Therapy, Capsida Debuts With $140 Million
The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.
April 28, 2021
 · 
3 min read
 · 
Heather McKenzie
Business
Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
April 23, 2021
 · 
3 min read
 · 
Brandon May
Business
CEO Salaries for the Top 20 Pharma Companies by Market Cap
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
April 23, 2021
 · 
3 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Job Trends
AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech
March 8, 2022
 · 
2 min read
BioMidwest
AbbVie to Present at the Cowen 42nd Annual Health Care Conference
March 1, 2022
 · 
1 min read
Deals
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
March 1, 2022
 · 
4 min read
Job Trends
AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn’s Disease in the U.S.
February 28, 2022
 · 
8 min read
BioMidwest
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
February 28, 2022
 · 
16 min read
Drug Development
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn’s Disease
February 24, 2022
 · 
22 min read
BioMidwest
AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
February 22, 2022
 · 
15 min read
Business
AbbVie Declares Quarterly Dividend - Feb 17, 2022
February 17, 2022
 · 
1 min read
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology
February 15, 2022
 · 
5 min read
BioCapital
Healis Therapeutics acquires ownership of key botulinum toxin patent
February 10, 2022
 · 
1 min read
Load More